Impact of New GLP-1 Medications on Employer-Sponsored Health Plans

The introduction of new oral GLP-1 medications for weight loss by pharmaceutical giants Novo Nordisk and Eli Lilly is set to boost consumer interest. However, these developments may present significant financial challenges for employer-sponsored health plans. Although the costs of these pills mirror those of injectable forms, the anticipated budgetary relief for employers remains elusive. A recent Business Group on Health survey highlights that 87% of employers expect an increase in demand for these oral medications, while few anticipate any decrease in costs.

According to a Mercer survey, nearly half of large employers provided coverage for GLP-1 medications by 2025. The rising costs, however, are a growing concern for many companies. An NFP survey reveals that 51% of employers believe GLP-1s significantly contribute to rising prescription drug costs. Nick Conway, president of Rx Solutions at NFP, emphasizes that the financial impact on pharmacy budgets could become unsustainable.

The list price for obesity drugs before insurance coverage ranges between $1,000 and $1,350 per month. Despite available discounts, employers may still face substantial expenses, potentially upwards of $550 per month per employee, as estimated by the Institute for Clinical and Economic Review. Such costs are likely to deter widespread adoption of these treatments in employee health plans.

Employee interest in accessing weight-loss medication is high, with 29% considering job changes to secure these benefits, according to NFP. Despite this demand, employers struggle to balance immediate expenses with the potential long-term health benefits of these drugs. Raymond Brown of Mercer points out the challenge of justifying costs without assured sustained use by employees. Ben Barner from Brown & Brown echoes concerns regarding discontinued use by employees, potentially undermining health benefits and cost savings.

Employers are reevaluating their coverage strategies. A Mercer survey revealed that some employers are reducing or planning to eliminate GLP-1 medication coverage in coming years due to cost concerns. Some companies are tightening eligibility criteria by requiring higher BMI thresholds or focusing coverage on patients with diabetes or specific behavior management needs, as noted by Eileen Pincay of Segal.

Despite the lack of significant efficacy differences between oral and injectable GLP-1s, cost efficiency remains a challenge. Jeff Levin-Scherz of WTW mentions that future inclusion of these drugs in employer plans might hinge on pharmacy benefit managers' policies and incentives. Alternative methods, such as reimbursement through health reimbursement arrangements or third-party weight management programs, are being explored. Direct-to-consumer programs offer another route, though still necessitating significant employee contributions.

Currently, limited competition among drug manufacturers contributes to high prices. However, upcoming market entrants could eventually drive costs down, as suggested by Ben Barner. Federal initiatives, such as offering GLP-1s through Medicare, alongside potential new competing products, could further influence future pricing dynamics. While the demand for GLP-1 medications is apparent, employers are cautiously evaluating how to manage these costs amidst evolving economic conditions and marketplace developments.